There are approximately 350 million carriers of hepatitis B in the world, and roughly 900K individuals die from hepatitis B each year, making it a liver disease not to be neglected.
Triggered by viruses, hepatitis B endangers liver functions, and prevents the liver from functioning, which leads to various liver diseases such as hepatitis liver cirrhosis, where severe cases can also result in liver cancer.
Despite having multiple therapeutic drugs, the treatment for hepatitis B starts from three years, and the virus is 90% likely to resurface and replicate upon withdrawal, where the possibility of the relapsed virus evolving into liver cirrhosis and liver cancer will also increase considerably. Aside from repeated use of medications, drug resistance is also a possible issue, which eventually leads to unavailability of drugs.
AntromaxTM effectively inhibits virus antigen and DNA activity of hepatitis B. By working with medical centers, clinical trials have proven that AntromaxTM assists in improving the virus load and liver panel of hepatitis B patients, with zero side effects.
